{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-071470","form_type":"8-K","ticker":null,"cik":"0001634379","company_name":"Metacrine, Inc.","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.938942+00:00","generated_at":"2026-06-18T02:05:07.547851+00:00","sec_items":["1.01","2.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Metacrine sells FXR program to Organovo for $4M cash","bullets":["Sold FXR program technology, including trial data and IP, to Organovo for $2.0M upfront and up to $2.0M additional.","Transaction closed on March 10, 2023; additional $2M due within 5 business days of delivery of certain assets.","Parties entered into a Patent Assignment for FXR-related intellectual property rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-071470","json":"https://secwatch.observer/filing/0001193125-23-071470.json","markdown":"https://secwatch.observer/filing/0001193125-23-071470.md","text":"https://secwatch.observer/filing/0001193125-23-071470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1634379/000119312523071470/0001193125-23-071470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1634379/000119312523071470/d474257d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T02:05:07.547851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f6969f6eb530b80f4d2500e61c7e90036a9587e5","claim":"Metacrine, Inc. completed a disposition involving Organovo, Inc. for $2.0 million in cash (closed 2023-03-10).","evidence_excerpt":"property rights relating to its FXR program. As consideration for the Assets, under the terms of the Asset Agreement, Purchaser paid the Company an upfront payment of $2.0 million in cash and agreed to make an additional payment of $2.0 million in cash within five business days of the Company’s delivery of certain assets sold pursuant to the Asset","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1634379/000119312523071470/0001193125-23-071470-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Organovo, Inc."},{"label":"Consideration","value":"$2.0 million in cash"},{"label":"Closing","value":"2023-03-10"}],"fact_type":"ma_transaction"},{"claim_id":"53b41406ddee1c2cd31de91f851dd4c591fb0923","claim":"Metacrine, Inc. entered into Asset Agreement with Organovo, Inc. valued at $2.0 million (effective 2023-03-10).","evidence_excerpt":"On March 10, 2023, Metacrine, Inc. (the “Company”) entered into and closed the transactions contemplated by that certain Asset Purchase Agreement (the “Asset Agreement”) with Organovo, Inc. (“Purchaser”), pursuant to which the Company sold to Purchaser the right, title and interest in and to its farnesoid X receptor (“FXR”) program technology including all inventory, trial data and research records relating to its FXR program (collectively, the “Assets”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1634379/000119312523071470/0001193125-23-071470-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Organovo, Inc."},{"label":"Value","value":"$2.0 million"},{"label":"Effective","value":"2023-03-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}